Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Should Clarify Coverage For Device Trials, Manufacturers Say

This article was originally published in The Gray Sheet

Executive Summary

Device manufacturers are asking for a clearer path to Medicare coverage of their clinical studies

You may also be interested in...



CMS Advisory Committee Supports Humanitarian-Device Trial Coverage

A Medicare advisory panel voted overwhelmingly Dec. 13 to allow coverage of all humanitarian-use devices in studies that fall under the agency's revised clinical research policy

CMS Advisory Committee Supports Humanitarian-Device Trial Coverage

A Medicare advisory panel voted overwhelmingly Dec. 13 to allow coverage of all humanitarian-use devices in studies that fall under the agency's revised clinical research policy

Advisory Committee To Discuss Changes To CMS’ Trial Payment Policy

CMS will seek guidance from the Medicare Coverage Advisory Committee (MCAC) Dec. 13 on revising its policy for reimbursing certain device clinical trial costs

Related Content

UsernamePublicRestriction

Register

MT023895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel